In Shing view, enterprises in different stages of development, volume and management differences are huge, so regardless of environmental factors and scenarios, blind mergers and acquisitions such as

Medicine Network September 20 News recently, medical device industry listed company Blue Sail medical release announcement, said the company raised 1.837 billion yuan for the acquisition of Bai Sheng International has been completed, the case is considered a-share history of the largest medical device merger case. September 13, Blue Sail medical issued a notice, said the company board has completed the re-election, the new board members formally unveiled, while the appointment of Li Bing-jong as the company president, Sun and other people as Vice president.

Lan Fan Medical said that after the completion of this round of mergers and acquisitions, listed companies will be in accordance with the Division mechanism to manage the existing line of business. In this regard, some market participants believe that this shows that investors are more enthusiastic about the Yu Lanfan Medical subscription, which is not easy in the recent downturn in the market environment.

However, for small and medium Medical devices Enterprise , the key to the present development lies in the competitiveness of the subdivision area, and the merger should not be rushed.

Public information shows that blue sail medical was established in 2003, formerly known as Shandong Blue Sail Plastic Co., Ltd., the main Health Production and sale of protective gloves. 2010, Blue Sail Medical officially landed a-share market.

2016 began to invest in the construction of 6 billion/year Nitrile glove Manufacturing Project, an annual output of 2 billion Nitrile glove project has been put into trial operation in June 2017.

In 2017, the trading plan was proposed to acquire a 93.37% stake in the park through a non-public offering, and to seek a natural extension and industrial upgrading of medical devices focused on high-value medical supplies.

It is understood that biosensors International headquarters in Singapore, 2017 stent sales of about 600,000, is second only to Abbott, Bo, Medtronic, the world's fourth largest Heart Stent manufacturing enterprises. Biosensors in the domestic wholly-owned subsidiary of Shandong Jiwei 2017 stent sales of 230,000-240,000, is one of the three big heart stent. Semi-annual report shows that the first half of this year, the Blue Sail health care to achieve operating income of 968 million yuan, attributable to the shareholders of the listed company's net profit of 148 million yuan, this time only to merge with the June business data of the group, but the revenue and attributable to the shareholders of the listed companies, respectively, the net profit increased 24% and 42.9 %.

At the same time, biosensors in the first half of the net income deduction of non-recurrent profit of 188 million yuan, accounting for 2018 full-year results of 380 million yuan commitment of 49.43%.

HENYEP Securities believes that the medical device circulation will be due to the rapid development of the industry, due to the new standard price reduction and concentration Purchase , circulation channels will face large-scale shuffle, but overall, the industry growth is still the trend.

But there are also some concerns about whether the company's existing executives can manage a global presence as a multinational for cardiovascular devices.

September 13, Blue Sail medical issued a notice, said the company board has completed the re-election, the new board members formally unveiled, while the appointment of Li Bing-jong as the company president, Sun and other people as Vice president. Public information shows that Li Bing-jong is a legendary figure in the Chinese medical device industry. He has served as chairman of Johnson (China) Medical Devices Co., Ltd., president of Johnson Greater China and vice President of North Asia International. When Li Bing-jong left Johnson in 2006, Johnson China's sales amounted to 2.7 billion yuan, making it the industry leader in Chinese medical devices.

He then joined Medtronic as President and International vice president of Medtronic Greater China, where Medtronic's Chinese medical device business maintained a compound growth rate of more than 40%.

Li Bing-jong has been in the two world giants such as Johnson and Medtronic, and has the management experience of heart, peripheral, digestive, respiratory, orthopedic, sugar, pain management and other business units, dazzling career history so that it can be called Chinese medical devices ' industry godfather '.

For the medical device industry continues to rise in the enthusiasm for mergers and acquisitions, analysts warned that small and medium-sized enterprises merger cannot be rushed. Shing, Hang Seng analyst of the China-new Jingwei analysis pointed out that the Chinese medical machinery industry structural differences, according to income and market share, the first echelon of enterprises (Mindray, Xinhua, etc.) has become a leading enterprise segments, the domestic market share of more than 10%, income in 10 billion yuan; The second echelon Enterprise (Le PU, diving, etc.) has just developed into a single product leader, income of about 2 billion yuan;

A large number of enterprises belong to the third Echelon, in less than 30% of the market share of the fight, the average volume just over 10 million yuan. Shing that the first echelon of enterprise development focus on cross-track mergers and acquisitions to break the industry ceiling; The second Echelon Enterprise merger and acquisition focus should be to seize the track market share and technology preservation;

The third echelon of the foothold lies in the construction of subdivision areas of competitiveness, mergers and acquisitions should not be hasty. "From the development of overseas giants can be seen, tamping their endogenous ability is the basis of large mergers and acquisitions, and the current domestic mergers and acquisitions are not successful in general because of insufficient volume and lack of management capacity."

In Shing view, enterprises in different stages of development, volume and management differences are huge, so regardless of environmental factors and scenarios, blind mergers and acquisitions such as Kezhouqiujian, impossible. A-share largest medical device merger case landed | SME merger should not be too hasty